KR910011818A - Aids 치료에 유용한 hiv 프로테아제 억제제 - Google Patents

Aids 치료에 유용한 hiv 프로테아제 억제제 Download PDF

Info

Publication number
KR910011818A
KR910011818A KR1019900021105A KR900021105A KR910011818A KR 910011818 A KR910011818 A KR 910011818A KR 1019900021105 A KR1019900021105 A KR 1019900021105A KR 900021105 A KR900021105 A KR 900021105A KR 910011818 A KR910011818 A KR 910011818A
Authority
KR
South Korea
Prior art keywords
hydroxy
phenyl
ethoxy
methyl
morpholinyl
Prior art date
Application number
KR1019900021105A
Other languages
English (en)
Inventor
제이. 톰슨 웨인
알. 허프 조엘
디. 영 스티븐
피. 박카 조셉
에이. 라일 테리
더블유. 형게이트 랜달
에프. 브리쳐 수잔
케이. 고시 아런
Original Assignee
제임스 에프. 너턴
머크 앤드 캄파니, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제임스 에프. 너턴, 머크 앤드 캄파니, 인코포레이티드 filed Critical 제임스 에프. 너턴
Publication of KR910011818A publication Critical patent/KR910011818A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

내용 없음

Description

AIDS 치료에 유용한 HIV 프로테아제 억제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (24)

  1. 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염.
    A-G-B-B-J (Ⅰ)
    상기식에서, A는 1)수소; 2)〔여기에서, R1은 수소이거나, a) ⅰ)C1-4알킬; ⅱ)하이드록시; ⅲ)카복시; ⅳ)할로〔여기서, 할로는 F, Cl, Br 또는 I이다); ⅴ)아미노; ⅵ)C1-3알콕시카보닐; ⅶ)테트라하이드로피란에 의해 치환되거나 비치환된 C1-3알콕시; ⅷ)-CONR2R3(여기서 R2및 R3은 동일하거나 상이하며, 수소, C1-5알킬 또는 C1-5알콕시 알킬이거나; R2및 R3이 함께 직접, 피롤리디날 또는 피페리딜과 같은 5원 내지 7원 헤테로사이클을 형성하거나; R2와 R3이 N, O 및 S 중에서 선택된 헤테로원자를 통해서는 R2와 R3이 결합되어 있는 질소원자와 함께 모르폴리닐, 피페라지닐 또는 N-C1-3알킬피페라지닐과 같은 6원 헤테로사이클을 형성한다); ⅸ)NR2R3;
    ⅹ)(여기서 R은 수소이거나 C1-4알킬이고;
    D는이며;
    R4는 N, C1-3알킬, C1-4알콕시 또는 NR2R3이다); xi)C3-7사이클로알킬; 또는 C6-10아릴 xii)푸릴 또는 모르폴리노와 같은 포화되거나 불포화된 5원 또는 6원 헤테로사이클이거나; 포화되거나 불포화된 7원 내지 10원 비사이클릭 헤테로사이클릭 환(여기서, 환(들)은 ⅰ)옥소, ⅱ)-OH, ⅲ)NH 또는 ⅳ)C1-4알킬에 의해 치환되거나 비치환된다); ⅷ) (a) 할로, (b) 하이드록시, (c) C1-3알콕시, (d) C1-3알킬, (e) NR2(여기서, R은 상기에서 정의한 바와 같다). (f), (g), (h) -CH2NR2, (j)또는 (k)중에서 선택된 1개 이상의 치환체에 의해 치환되거나 비치환된 C6-10아릴 또는 C6-10카보사이클릭; 및 xiv) -O-〔CH2)mO〕n-R (여기서, m은 2 내지 5이고, n은 0 내지 5이다) 중에서 선택된 1개 이상의 치환체에 의해 치환되거나 비치환된 C1-6알킬 또는 C1-6알케닐; b) ⅰ)C1-4알킬, ⅱ)C1-3알콕시, ⅲ)하이드록시, ⅳ)할로, ⅴ)-NR2, ⅵ), ⅶ), ⅷ) -SO2NR2, ⅸ) -CH2NR2, ⅹ) -NRCOR 또는 xi) -NRSO2R중에서 선택된 1개 이상의 치환체에 의해 치환되거나 비치환된 C6-10아릴; 또는 c) 5원 또는 6원 헤테로사이클이다〕; 3) R1-SO2-; 4)(여기서, R5는 H 또는 C1-5알킬이거나, R5는 R1과 함께 직접, 피롤리디닐 또는 피페리디닐과 같은 5원 내지 7원 헤테로사이클을 형성하거나 R1과 R5가 N, O 및 S중에서 선택된 헤테로원자를 통해서 R1과 R5가 결합되어 있는 질소원자와 함께 모르폴리닐, 피페리지닐 또는 N-C1-3알킬- 피페라지닐과 같은 6원 헤테로사이클을 형성한다); 5)〔여기서, R6, R7및 R6은 독립적으로 a) H; b) ⅰ) 할로, ⅱ) OH, ⅲ) 아릴 SO2- 및 ⅳ) -O-〔CH2)mO〕n-R 중에서 선택된 1개 이상의 치환체에 의해 치환되거나 비치환된 C1-6알킬, ⅰ)C1-4알킬, ⅱ) C1-3알콕시, ⅲ) 할로, ⅳ) 니트로, ⅴ) 아세톡시, ⅵ) 디메틸아미노카보닐, ⅶ) 페닐 및 ⅷ) C1-3알콕시카보닐중에서 선택된 1개 이상의 치환체에 의해 치환되거나 비치환된 아릴; d) 플루오르에닐; e) R6, R7및 R8은 독립적으로 결합되어 C3-10사이클로알킬(예:아다만틸), 사이클로펜틸 또는 사이클로헥실인 모노사이클릭, 비사이클릭 또는 트리사이클릭 환계를 형성할 수 있으며, 또한 C1-4알킬에 의해 치환될 수 있거나; f) 피리딜, 푸릴, 1,3-디옥슬란 또는 테트라 하이드로푸릴과 같은 포화되거나 불포화된 5원 내지 7원 헤테로사이클릭 환이거나; 벤즈이속사졸릴 또는 4H-1,3-벤조디옥신과 같은 포화되거나 불포화된 7원 내지 10원 비사이클릭 헤테로사이클릭 환((들)은 C1-4알킬에 의해 치환되거나 비치환된다)이거나; g) R6, R7및 R8은 독립적으로 결합되어 5원 내지 7원 헤테로사이클릭 환을 형성할 수 있거나; ⅰ) 아세틸옥시, ⅱ) C1-4알킬, ⅲ) 하이드록시, ⅳ) 하이드록시 C1-4알킬, ⅴ) 알킬옥시알킬, ⅵ) 페닐 알콕시 및 ⅶ) 알콕시중에서 선택된 1개 이상의 치환체에 의해 치환되거나 비치환된 포화되거나 불포화된 7원 내지 10원 비사이클릭 헤테로 사이클릭 환을 형성할 수 있다〕; 또는
    8)
    〔여기에서, Z는 O,S 또는 HH이고; R4및 R10은 독립적으로 a) -(CH2)n-R11또는 b) C1-4알케닐 -R4(여기서 n은 0 내지 5이다)이고; R9및 R10은 각각 또는 둘다 R12에 의해 치환되어야 하며; R11은 a) 수소; b) C1-4알킬; c) 하이드록시로 임의로 치환된 C5-C10사이클로알킬, d) R12로 치환되거나 비치환되고, 하나 이상의 ⅰ) 할로, ⅱ) C1-4알킬, ⅲ) C1-3알콕시 또는 ⅳ) 하이드록시로 임의로 치환된 C6-C10아릴; 또는e)N,O,S중에서 선택된 1 내지 3개의 헤테로원자를 함유하는 모노사이클릭 또는 비사이클릭 헤테로사이클 〔여기서, 헤테로사이클은 비치환되거나 R12및 임의로 하나 이상의 i) 할로, ⅱ)C1-4알킬 또는 ⅲ)C1-3알콕시로 치환된 것이다)이고; R12는 a)-X-(CH2)m-NR13R14〔여기서, X는 -O-, -S- 또는 -NH-이고 m은 2 내지 5이며, R13및 R14는 독립적으로 수소이거나 i)C1-6알킬, ⅱ)하나 이상의 (a)C1-3알콕시, (b)-OH 또는 (c)-NR2(여기서, R은 수소 C1-4알킬이다)로 치환된 C1-6알킬, ⅲ)동일하거나 상이하며 함께 결합되어 -NR, -O-,-S-,또는 -SO2- 중에서 선택된 추가 헤테로원자수 2의 모르폴리노와 같은 5 내지 7원 헤테로사이클을 형성하고 (여기서, 헤테로사이클은 임의로 C1-4알킬로 치환된 것이다); iv)비치환디거나 하나이상의 (a) C1-4알킬 또는 (b)-NR2로 치환되거나 비치환된 방향족 헤테로사이클이다〕; b)-(CH2)q-NR13R14〔여기서, q는 1 내지 5이고,R13및 R14는 상기에서 정의한 바와 같으나, R13또는 R14는 H 또는 C1-6알킬이 아니다〕; 또는 c) 벤조푸릴, 인돌릴, 아자사이클로알킬, 이지비사이클로 C7-11사이클로알킬, 또는 비치환되거나 C1-4알킬로 치환된 벤조 피페리디닐미며, R15는 -OH 또는 - NHR16〔여기서 , R16은 -H, -,- C1-4알킬 또는 -COOR 이다〕이고;는 1) 하나 이상의 (a) C1-4알킬; b) 하이드록시; c) -NR2; d) -COOR; e)- CONGR;f) -NHSO2R; g); h) 아릴; i) C1-4알킬로 치환된 아릴; j) 헤테로사이클; 또는 k) C1-4알킬로 치환된 헤테로사이클로 치환되거나 비치환된 C3-17사이클로알킬이고,
    [여기서, R16은 상기에서 저의한 바와 같고, X는 O.S 또는 NH 이며, W는 1) OH, 2) NH23) OR, 또는 4) NHR 이다〕이며, B는 존재하지 않거나 독립적으로 -[여기서, R21은 a)-CH(CH3)2, b)-CH(CH3) (CH2CH3) 또는 c)-페닐이다〕이고, J는 1) YR17[여기서, Y는 O 또는 NH 이고, R17은 a)H; b) -C1-6알킬, 하나이상의 ⅰ)-NR2, ⅱ) -OR, ⅲ) -NHSO2C1-4알킬, ⅳ) -NHSO2아릴, 또는 -NHSO2(디알킬-아미노아릴), v) -CH2OR, vi) -C1-4알킬, vii)viii)ix)또는x)xi)xii)xiii) -NR3A(여기서, A는 반대이온이다), xiv) -NR18R18(여기서, R18및 R19는 동일하거나 상이하며 C1-5알킬과 함께 결합하여 -O-, -S-, 또는 -NR-중에서 선택된 하나이하의 추가의 헤테로원자를 함유하는 5 내지 7원 헤테로사이클을 형성한다), xv) 아릴, xvi) -CHO, xvii, -OR(O)(ORx)2(여기서 Rx는 H 또는 아릴이다), 또는 xviii) 하나이상의 아민 또는 4급 아민 또는 -O-[(CH2)mO]n-R 로 치환된알킬; 또는 -OP(O)(ORx)2로 치환되거나 비치환된 -C1-6알킬; 또는 c)-O-[(CH2)mO]nO]nH이다], 2)N(R17)2, 또는 3) -NR18R19[여기서, R15및 R19는 상기에서 정의한 바와 같다], 또는 4)[여기서, Y, R17및 n은 상기에서 정의한 바와 같고, R20은 a) 수소; b)하나이상의) i)할로, ii)-OR (여기서, R은 H 또는 C1-4알킬이다), iii)iv)v) -CH2NR2, vi) -SO2NR2, vii) -NR2, viii)xi) C1-4알킬, x) 페닐, xi) -CF3, xii)xiii) -C1-4알킬 -NR2xiv) -OP(O)(ORx)2(여기서, Rx는 H또는 아릴이다). 또는 xv) 하나이상의 아민 또는 4급 아민으로 치환된알킬 또는 -OP(O)(ORx)2로 치환되거나 비치환된 아릴; c)치환되거나 비치환된 5 내지 7원 헤테로사이클릭환 또는 7 내지 10원 비사이클릭 헤테로사이클릭환, 예를들면, 이소크로만, 크로만, 이소티오크로만, 티오크로만, 벤즈이미다졸, 벤조티오피란, 옥소벤조 티오피란, 벤조피란, 벤조티오파라닐설폰, 벤조티오파라닐설폭사이드(여기서, 환 또는 환들은 하나 이상의 i) 할로, ii)-OR(여기서, R은 H, C1-4알킬 또는 C1-4알케닐이다)(여기서, Rx는 H 또는 아릴이다), xv) 하나이상의 아민 또는 4급 아민 또는 -OP(O)(ORx)2치환된치환되거나 비치환된다); d)포화되거나 불포화된 5 내지 7원 카보사이클릭 또는 7 내지 10원 비사이클릭 카보사이클릭 환, 예를들면 사이클로펜탄, 사이클로헥산, 인단, 노르보란 또는 나프탈렌(여기서, 카보사이클릭 환은 하나이상의 i) 할로 ii)-OR 또는 -CH2OR(여기서, R은 H 또는 C1-4알킬이다),(여기서, R21은 H, -(CH2)n-NR2, C1-16알킬, 피리딘, -(CH2)nNR-(CH2)n-NR2, -(CH2)n,-[(CH2)mO]n-R,R로 치환된 퀴뉴클리디니우밀, 1회 이상 R로 치환된 피페라진 -C1-4알킬-벤질 또는 모르폴리노알킬벤질이다), iv), v)-CH2NR2, vi) -SO2NR2, vii) -NR2, viii)xi) C1-6알킬, x)페닐, xi) -CF3,xiii) -OP(O)(ORx)2(여기서, Rx는 H 또는 아릴이다) xiv) 하나이상의 아민 또는 4급 아민으로 치환된알킬, -OP(O)(ORx)2, 또는 -O-[(CH2)mO]n-R 또는로 치환되거니 비치호나 된다)이다]이다.
  2. 제1항에 있어서,인 화합물.
  3. 제2항에 있어서, B가 존재하지 않거나 존재하고 Q가인 화합물.
  4. 제3항에 있어서, B가 존재하지 않고 J가 NH-R16(여기서, R20은 7원 내지 10원 포화 또는 불포화 비사이클릭 카보사이클릭 또는 헤테로사이클릭환이다)인 화합물.
  5. N-(2-(R)-하이드록시-1(S)-인다닐)-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2-(R)-하이드록시-1(S)-인다닐)-5(S)-((2-테트라하이드로푸라닐)카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2-(R)-하이드록시-1(S)-인다닐)-5(S)-(2-하이드록시에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐메틸)헥산아미드, N-(2-(R)-하이드록시-1(S)-인다닐)-5(S)-(1-메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2-(R)-하이드록시-1(S)-인다닐)-5(S)-(에록시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2-(R)-하이드록시-1(S)-인다닐)-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-(4-(2-(4-모폴리닐)에톡시)페닐)-2(R)-(3'-페닐프로프-2-',엔-1-일)-헥산아미드, N-(2-벤즈아미돌릴메틸)-N-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-(4-(2-(4-모폴리닐)에톡시)페닐)-2(R)-(3'-페닐프로프-2-',엔-1-일)-헥사노일 이소로이실 아미드, N-(2-벤즈아미돌릴메틸)-N-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)헥사노일 이소로이실 아미드, N-))피롤로[3,2-b]피리딘-2-일)메틸)-N'-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐-헥사노일 이소로이실 아미드, N-((5-(2-모폴리닐에틸)피롤로[3,2-b]피리딘-2-일)메틸)-N'-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-(4-(2-(4-모폴리닐)에톡시)페닐)-2(R)-(3'-페닐프로프-2-',엔-1-일)-헥사노일 이소로이실 아미드, N-(2(R)-하이드록시-1(S)-인다닐-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((3-(2-(4-모폴리닐)에톡시)페닐)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-(4-(2-(4-모폴리노)에톡시)페닐-2(R)-페닐메틸핵산아미드, N-(2(S, 3-(R)-하이드록시-1(S)-인다닐)-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-(4-(2-(4-모폴리닐)에톡시)페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)핵산아미드, N-(2(R)-하이드록시-1(S)-벤조피라닐)-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-(4-(2-(4-모폴리노)에톡시)페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)핵산아미드, N-(2(R)-하이드록시-1(S)-벤조피라닐)-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-(4-(2-(4-모폴리노)에톡시)페닐-2(R)-(4-하이드록시페닐)-메틸)핵산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)핵산아미드, N-(2(S),3-(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((3-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(S),3-(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((3-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R),-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-(4-(2-(4-모폴리닐)에톡시)페닐)2-(R)-((3-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(S),3-(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((3-(2-(4-모폴리닐)프로필옥시)페닐)메틸)헥산아미드, N-(2(S)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((3-(2-(4-피롤리디닐)에톡시)페닐)메틸)헥산아미드, N-(2(S),-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-디메틸아미노에톡시)페닐)메틸)헥산아미드, N-(2(S),-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(1-피페리디닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(1-피롤리디닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(N,N-비스(2-메톡시에틸(아미노)에톡시)페닐)-메틸)헥산아미드, N-(2(R),-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-티아모폴린-4-일)에톡시)페닐)메틸)헥산아미드, N-(2(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-(1-옥소티아모풀린-4-일)에톡시)페닐)메틸)헥산아미드, N-(2(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-(1,1-옥소티아모풀린-4-일)에톡시)페닐)메틸)헥산아미드, N-(2(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(1-(4-메틸피페라진-1-일)에톡시)페닐)메틸)헥산아미드, N-(2(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(S)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-디메틸아미노아세톡시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-아세톡시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(S), 3(R)-디아세톡시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(3-(3-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(3-(4-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(5-(2-(4-모폴리닐)에톡시)-2-벤즈아미다졸릴-메틸))-5(S)-1,1-디메틸에톡시카보닐아미노-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)벤즈이미다졸릴메틸)5(S)-(1,1-디에틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(2-메틸프로필아미노)에톡시)페닐)메틸)헥산아미드, N-(3(R)-아미노-2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-((3-피리딘키보닐옥시)-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-n-헥사데카노일옥시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2-(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(3,5-디메틸모풀린-4-일)에톡시)페닐)메틸)헥산아미드, N-2-(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(2,6-디메틸모풀린-4-일)에톡시)페닐)메틸)헥산아미드, N-(2-(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(2,2,6,6-테트라메틸피페리딘-4-일)-아미노-에톡시)페닐)메틸)헥산아미드, N-2-(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(3-(4-모폴리닐)프로필)페닐)메틸)헥산아미드, N-2-(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(4-모폴리닐)메닐페닐)메틸 헥산아미드, n-(2-(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(3-(비스(2-메톡시에틸)아미노)프로필)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐(-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)하이드록시-6-페닐-2(R)-((4-(3-(1-티아모풀린-4-일)프로필)페닐-메틸)헥산아미드, N-(2(R)-아미노-2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(1-이미다졸릴)에톡시)페닐)메틸)헥산아미드, N-(3(R)-아미노-2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(1-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-아미노-2(R)-하이드록시-1(S)-인다닐)-5(S)-1(1,2-디메틸-2-하이드록시에틸)포스토로아미데이토-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드,
    하이드록시-6-페닐-2(R)-((4-92-(4-모폴리닐)에톡시)페닐)메틸)헥산이미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1-비사이클로[2,2,1]헵틸옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(메톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-((2-테트라하이드로푸라닐)메톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-((3-테트라하이드로푸라닐)메톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1-메틸-1-(2-테트라하이드로푸라닐)에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1-메틸-1-(3-테트라하이드로푸라닐)메톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3-테트라하이드로피라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3-테트라하이드로피라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4-테트라하이드로피라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-테트라하이드로피라닐)메톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-메톡시아세틸아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-(2-메톡시에톡시)아세틸아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-(2-(2-메톡시에톡시)아세탈아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-((2(R)-테트라하이드로푸라닐)카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-((2(S)-테트라하이드로푸라닐)카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3-테트라하이드로푸라닐)카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-메틸프로필옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-메톡시에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-메톡시에톡시)에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-(2-(2-메톡시에톡시)에톡시)에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에록시카보닐-N-메틸아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디ㅣㅣ메틸에톡시에톡시)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-((카보벤질옥시)아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4-피리딜메틸옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(n-프로필옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(n-부틸옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(n-펜틸옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-3(S),4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(4(R)-하이드록시-2(R)-메틸-1(R)-사이클로펜틸)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(4(R)-하이드록시-2(R)-메틸-1(R)-사이클로펜틸)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(4(R)-하이드록시-2(R)-메틸-1(R)-사이클로펜틸)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(4(R)-하이드록시-2(R)-메틸-1(R)-사이클로펜틸)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-5(S-메틸-1(S)-사이클로펜틸)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R),3(R)-디하이드록시-5(R)-메틸-1(S)-사이클로펜틸)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R),3(R)-디하이드록시-5(S)-메틸-1(S)-사이클로펜틸)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-3(S)-디하이드록시-4(S)-티오크로마닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-1(S)-옥소-4(R)-티오크로마닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-사이클로[4,3,0]노닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(1(R,S)-옥소-4(S)-이소티오크로마닐-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐-5(S)-(1,1-디메틸에톡시카보닐)아미노)-4(S)-하이드록시-6-페닐-2(R)-[4-(2-(4-아자비사이클로[2,2,2.]옥타닐-1-아미뉴밀)에톡시)-페닐메틸헥산아미드, N-[(1-하이드록시사이클로헥실)메틸]-5(S)-t-부톡시카보닐아미노-4(S)-하이드록시-6-페닐02(R)-(4-[2-모폴리노에톡시]-페닐)메틸헥산아미드, N-(3(S)-아미노-2(R)-하이드록시-1(S)-인다닐)-(S)-t-부톡시카보닐아미노-(4S)-하이드록시-6-페닐-2(R)-(4-[2-모폴리노에톡시]-페닐)메틸헥산아미드, N-(2(R)-하이드록시-3A,4,,5,6,7,7A, 헥사하이드로-인단-1(S)-일)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-2(R)-((3-카복시프로파노일)옥시)-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-석시노일아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노)에톡시)페닐메틸]헥사아미드, N-(2(R)-[(2-(2-(2-메톡시에톡시)에톡시)에톡시)-카보닐]옥시)-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시-카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4-테트라하이드로피라닐카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4-테트라하이드로피라닐)아세트아미도)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-[(시스-2(R)-(1'-메틸-3'(S)-퀴누클리디뉴밀카보닐)옥시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-[4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-아세틸아미노-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-[(시스-2(R)-[4-(4-메틸-1-피페라지닐메틸)벤조일]옥시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-[4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-[(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[2(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-부티닐아미노]-4(S)-하이드록시-6-페닐-2(R)-[4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-[(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[(5-옥소-2(S)-하이드록시-6-페닐-2(R)-[4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-[(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[2(S)(아미노-4-하이드록시부틸릴)아미노]-4(S)-하이드록시-6-페닐-2(R)-[4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐-5(S)-[1-트란스-(2-하이드록시인다닐리데닐)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)0[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[1-시스-(2-하이드록시인다닐데닐)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]-헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[(2-하이드록시-1인다닐메틸)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[(4-모폴리닐)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]-헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(시스-2(S)-하이드록시-1(S)-벤조피라닐-5(S)-(2-메톡시에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(시스-2(S)-하이드록시-1(S)-벤조피라닐-5(S)-(3,6,9,12-테트라옥사트리데실카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐-5(S)-(헥사하이드로푸로[2,3-b]푸라닐-3A-옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(시스-2(R)-하이드록시01(S)-인다닐)-5(S)-[(2,2-디메틸-1,3-디옥슬란-메틸옥시)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에폭시)페닐)메틸]헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-푸라닐메톡시카보닐아미노-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리노)에톡시)페닐)메틸-6-사이클로헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-((3-(R,S)-테트라하이도로푸라닐)아세트아미드)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리노)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-((2(R,S)-테트라하이드로푸라닐)아세트아미노-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-((4,5-디하이드로-3(2H)-푸릴리덴)하세트아미도)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-케닐피페라지닐)에톡시)페닐)메틸헥산-아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-[(2-푸라닐메틸옥시카보닐]아미노)-4(S)-하이드록시-6-페닐-2(R)-(3-(4-(2-모폴리노에톡시)페닐프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-[(2-메톡시에톡시)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[3-(4-(2-모폴리노에톡시)페닐프로프-2-엔-1-일)헥산아미드, N-(2(R)-(3-(4-(2-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐)아미노-4(S)-하이드록시-6-사이클로헥실-2(R)-(3-(4-(2-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐)아미노-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(디에틸아미노)에톡시)페닐)메틸-헥산아미드, N-2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1,-디메틸에톡시카보닐아미노-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(디이소프로필아미노)에톡시)페닐)메틸-헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노-4(S)-히이드록시-6-(4-(2-디메틸아미노에톡시)페닐)-2(R)-(3-페닐-2-프로펜-1-일)-헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(R,S-테트라하이드로피라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(5-(R)-메톡시메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시)-1(S)-인다닐)-5(S)-(5-(2-아세톡시-1,4:3,6-디안하이드로-D-글루시틸)카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록ㄷ시-1(S)-인다닐)-5(S)-(3(S)-메틸-3-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-4(S)-하이드록시-5(S)-(하이드록시메틸)-3(R)-테트라하이드로푸라닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-4(S)-벤질옥시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모플리닐)에톡시)페닐)메틱헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-4(R)-벤질옥시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4(S)-메톡시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모플리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4(R)-메톡시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(5(S)-메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틱헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(5(S)-메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-6-페닐-2(R)-(4-(2-(4-모플리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(5(R)-메톡시메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(5-(R)-메톡시메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(5-(2-아세톡시-1,4:3,6-디안하이드로-D-글루시틸)카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드,N-(2(R)-하이드록시-1(S)-인다닐) -5(S)-3(S) -메틸-3-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드,N-92(R)-하이드록시-1(S)-인다닐)-5(S)-4(S)-하이드록시-5(S)-(하이드록시메틸)-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4(S)-벤질옥시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4(R)-벤질옥시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4-(S)-하이드록시-6-페닐-2(R)-4(2-(2-모폴리닐)에톡시)페닐)메틸헥산아미드,N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-4(S)-메톡시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드,N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4(R)-메톡시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-5(S)-메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노(-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(6(S)-메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노(-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(5(R)-메톡시메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-5(S)-메톡시메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(시스-2(S)-하이드록시-1(S)-벤조피라닐-5(S)-(2-메톡시에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(시스-2(S)-하이드록시-1(S)-벤조피라닐-5(S)-(3,6,9,12-테트라옥사트리데실카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-[4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(헥사하이드로푸로[2,3-b]푸라닐-3A-옥사카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-모폴리닐]에톡시)페닐)메틸헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인디닐)-5(S)-[(2,2-디메틸-1,3-디옥슬란-메틸옥시)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[(2-푸라닐메톡시)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(2R)-하이드록시-1(S)-인다닐)-5(S)-(N'-아세틸네우르아미노일]아미노-4(S)-하이드록시-6-페닐-2(R)-[4-(2-모폴리노에톡시)페닐]메틸헥산아미드, N-(2R)-하이드록시-1(S)-인다닐)-5(S)-(1,3-비스(메톡시에톡시))프로폭시카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[4-(2-(4-모폴리노에톡시)페닐]메틸헥산아미드, N-(2R)-하이드록시-1(S)-인다닐)-5(S)-[5(R)-하이드록시메틸-3(S)-메톡시테트라하이드로푸라닐옥시아미노-4(S)-하이드록시-6-페닐-2(R)-[4-(2-(4-모폴리노에톡시)페닐)메틸]헥산아미드, 2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-메틸-3-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-4(S)-하이드록시-5(S)-(하이드록시메틸)-3(R)-테트라하이드로푸라닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-4(S)-벤질옥시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모플리닐)에톡시)페닐)메틱헥산아미드, N-(시스-(2(R)-하이드록시-1(S)-인다닐)-5(S)-[(3-메톡시-1-부틸옥시)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-(4-모풀리노에톡시)페닐)메틸]헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[(1-메톡시-2-프로필옥시)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-[(2-(1,3-비스(메톡시)프로폭시카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-(4-모폴리노)에톡시)페닐)메틸헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[(2-(1,4-벤조디옥사닐)메틸)옥시카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(2,2-디옥스-4(S)-이소티오크로마닐)-5(S)-[1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(2(R, S )-옥소-4(S)-이소티오크로마닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[(2,3-비스-메톡시에틸옥시)프로필카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[4H-테ㅡ라히드로-4-피라닐옥시메틸카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-[1,1-디메틸에톡시카보닐아미노-4(S)-하이드록시-6-사이클로헥실-2(R)-[4-(2-(4-모폴리노)에톡시)(페닐메틸]헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[1,1-디메틸에톡시카보닐-L-아스파리기닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(4(S)-이소티오크로마닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-[4-(2-(4-모폴리노)에톡시)페닐메틸]헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[1,1-디메틸에톡시카보닐-L-아스파라기닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(4(S)-이소티오크로마닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-1(S)-안다닐)-5(S)-[[N-2-퀴놀릴카보닐-L-아스파라기닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[[4-(2-모폴리노에톡시)페닐)메틸)헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[[N-2-퀴놀릴카보닐-L-아스파라기닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-네트라하이드로푸라닐)아세트아미노-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-케닐피페라지닐)에톡시)페닐)메틸헥산-아미드, N-(2R)-하이드록시-1(S)-인다닐)-5(S)-[(2-푸라닐메틸옥시카보닐]아미노)-4(S)-하이드록시-6-페닐-2(R)-[3-(4-(2-모폴리노에톡시)페닐프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-[(2-메톡시에톡시)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[3-(4-(2-모폴리노에톡시)페닐프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐)아미노-4(S)-하이드록시-6-사이클로헥실-2(R)-(3-(4-(2-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐)아미노-4(S)-하이드록시-6-사이클로헥실-2(R)-(3-(4-(2-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐)아미노-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(디에틸아미노)에톡시)페닐)메틸-헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(디이소프로필아미노)에톡시)페닐)메틸-헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보니아미노)-4(S)-하이드록시-6-(4-(2-디메틸아미노에톡시)페닐)-2(R)-(3-페닐-2-프로펜-1-일)-헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(R,S-테트라하이드로피라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(5-(1-아세톡시-1,4 : 3,6-디안하이드로-D-글루시틸)카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2R)-하이드록시-1(S)-인다닐)-5(S)-4(S)-하이드록시-5(S)-(하이드록시메틸)-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4(S)-벤질옥시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(5(S)-메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(5(S)-메톡시메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4(S)-메톡시-5(S)-메톡시메틸-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2R)-하이드록시-1(S)-인다닐)-5(S)-(4(S)-메톡시-5(S)-메톡시메틸-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(트란스-3-(4-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(트란스-3-(4-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1-(S)-인다닐)-5(S)-(3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(트란스-3-(4-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로푸라닐옥시카보니랑미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(트란스-3-(4-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(R)-인다닐)-5(S)-(3(S)-테트라하이드로피라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(트란스-3-(4-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(S)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-디에틸아미노에톡시)페닐)메틸)헥산아미드, N-(2-2(R)-하이드록시-1(S)-인다닐)-5(S)-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-N,N-디-2-프로필)아미노에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4( S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-N,N-디-2-프로필)아미노에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로포라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-메틸-1-피페라지닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로피라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-메틸-1-피페라지닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-)(3(S)-1,1-디옥소테트라하이드로티오푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(트란스-3-(4-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-1,1-디옥소테트라하이드로티오푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(트란스-3-(4-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-메틸-1-피페라지닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-1,1-디옥소테트라하이드로티오푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-메틸-1-피페라지닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-1,1-디옥소테트라하이드로티오피라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(트란스-3-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-1,1-디옥소테트라하이드로티오피라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(트란스-3-(4-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-1,1-디옥소테트라하이드로티오피라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(트란스-3-(4-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-1,1-디옥소테트라하이드로티오피라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-메틸-1-피페라지닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4(S)-하이드록시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4(R)-하이드록시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4(R)-메틸-3(S)-태트라하이드로푸라닝록시카비놀아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-메톡시에톡시-카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-5-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드인 화합물 또는 이의 약저학적으로 허용되는 염.
  6. N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모프폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(N,N-비스(2-메톡시에틸)아미노)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1-메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모르폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐-5(S)-에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모르폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-모르폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-모르폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-1,1-디메틸에톡시카보닐아미노)-4-(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-메틸-1-피레라지닐)에톡시)페닐)멘틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-메틸-1-피페라지닐)에톡시)페닐)메틸)헥산아미드,N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(N.N-디-2-프로필)아미노에톡시)페닐)메틸헥산아미드, N-(2R)-하이드록시-1(S)-인다닐)-(S)-(3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하일드록시-6-사이클로헥실-2(R)-(4-(2-(4-메틸-1-피페라지닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(트랜스-3-(4-(2-(4-모르폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(트랜스-3-(4-(2-(4-모르폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인디닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(트랜스-3-(4-(2-(4-모르폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(트랜스-3-(4-(2-(4-모르폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드 또는 N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-메톡시에틸옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(트랜스-3-(4-(2-(4-모르폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드인 화합물 또는 이의 약제학적으로 허용되는 염.
  7. N-(2R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모프롤리닐)에톡시)페닐)메닐)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(N,N-비스(2-메톡시에틸)아미노)에톡시)페닐)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1-메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모르폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모르폴리닐)에톡시)페닐)메틸)헥산아미드인 화합물 또는 이의 약제학적으로 허용되는 염.
  8. 제7항에 있어서, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모르폴리닐)에톡시)페닐)메틸)헥산아미드인 화합물 또는 이의 약제학적으로 허용되는 염.
  9. 제7항에 있어서, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(N,N-비스(2-메톡시에틸)아미노)에톡시)페닐)메틸)헥산아미드인 화합물 또는 이의 약제학적으로 허용되는 염.
  10. 제7항에 있어서, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모르폴리닐)에톡시)페닐)메틸)헥산아미드인 화합물 또는 이의 약제학적으로 허용되는 염.
  11. 제7항에 있어서, N-(2-(R)-하이드록시-1(S)-인다닐)-5(S)-(에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모프르폴리닐)에톡시)페닐)메틸)헥산아미드인 화합물 또는 이의 약제학적으로 허용되는 염.
  12. 표의 항비루스제, 면역조절제, 항생제 또는 백신과의 배합물로의 제1항 내지 11항 중 어느 한 항의 화합물.
  13. 제1항 내지 11항중 어느 한 항의 화합물 및 약제학적으로 허용되는 담체를 함유하는 약제학적 조성물.
  14. 제12항에 따른 배합물의 화합물 및 약제학적으로 허용되는 담체를 함유하는 약제학적 조성물.
  15. 제13항에 있어서, AIDS의 치료, HIV에 의한 감염의 예방, HIV에 의한 감염의 치료 또는 HIV 프로타아제의 억제에 있어 사용하기 위한 약제학적 조성물.
  16. 제14항에 있어서, AIDS의 치료, HIV에 의한 감염의 예방, HIV에 의한 감염의 치료 또는 HIV 프로타아제의 억제에 있어 사용하기 위한 약제학적 조성물.
  17. 유효량의 제1항 내지 11항중 어느 한 항의 화합물을 투여함을 특징으로 하여 AIDS를 치료하는 방법.
  18. 유효량의 제12항에 따른 배합물로의 화합물을 투여함을 특징으로 하여 AIDS를 치료하는 방법.
  19. 유효량의 제1항 내지 11항중 어느 한 항의 화합물을 투여함을 특징으로 하여 HIV에 의한 감염을 예방하는 방법.
  20. 유효량의 제12항에 따른 배합물로의 화합물을 투여함을 특징으로 하여 HIV에 의한 감염을 예방하는 방법.
  21. 유효량의 제1항 내지 11항 중 어느 한 항의 화합물을 투여함을 특징으로 하여 HIV에 의한 감염을 치료하는 방법.
  22. 유효량의 제12항에 따른 배합물로의 화합물을 투여함을 특징으로 하여 HIV에 의한 감염을 치료하는 방법.
  23. 유효량의 제1항 내지 11항중 어느 한 항의화합물을 투여함을 특징으로 하여 HIV 프로테아제를 억제하는 방법.
  24. 유효량의 제12항에 따른 배합물로의 화합물을 투여함을 특징으로 하여 HIV 프로테아제를 억제하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900021105A 1989-12-18 1990-12-18 Aids 치료에 유용한 hiv 프로테아제 억제제 KR910011818A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US45291289A 1989-12-18 1989-12-18
US452912 1989-12-18
US59728690A 1990-10-15 1990-10-15
US597286 1990-10-15
US61965490A 1990-12-04 1990-12-04
US619654 1990-12-04

Publications (1)

Publication Number Publication Date
KR910011818A true KR910011818A (ko) 1991-08-07

Family

ID=27412551

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900021105A KR910011818A (ko) 1989-12-18 1990-12-18 Aids 치료에 유용한 hiv 프로테아제 억제제

Country Status (12)

Country Link
EP (1) EP0434365A3 (ko)
JP (1) JPH05345775A (ko)
KR (1) KR910011818A (ko)
CN (1) CN1053607A (ko)
AU (1) AU6822990A (ko)
CA (1) CA2032259A1 (ko)
FI (1) FI906212A (ko)
HU (1) HU908295D0 (ko)
IE (1) IE904555A1 (ko)
IL (1) IL96691A0 (ko)
NO (1) NO905428L (ko)
PT (1) PT96234A (ko)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
CA2093429A1 (en) * 1990-10-09 1992-04-10 Shieh-Shung T. Chen Process for biophosphorylating organic compounds
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
US5508407A (en) * 1991-07-10 1996-04-16 Eli Lilly And Company Retroviral protease inhibitors
DK0528762T3 (da) * 1991-08-15 1997-08-25 Ciba Geigy Ag N-acyl-N-heterocyclyl- eller naphthylalkyl-aminosyrer som angiotensin II antagonister
CA2076204A1 (en) * 1991-08-16 1993-02-17 Samuel L. Graham Hiv protease inhibitors with n-terminal polyether substituents
EP0534511A1 (en) * 1991-08-16 1993-03-31 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids
US5643878A (en) * 1991-09-12 1997-07-01 Ciba-Geigy Corporation 5-amino-4-hydroxyhexanoic acid derivatives
US5491149A (en) * 1991-09-16 1996-02-13 The Du Pont Merck Pharmaceutical Company Dihydroxypropylamine containing retroviral protease inhibitors
HU221816B1 (hu) 1991-10-11 2003-01-28 Bristol-Myers Squibb Pharma Company Gyűrűs karbonil vegyületek, és ezeket tartalmazó gyógyászati készítmények
WO1993008184A1 (en) * 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
CA2195027C (en) * 1991-11-08 2000-01-11 Joseph P. Vacca Hiv protease inhibitors useful for the treatment of aids
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
AU3240493A (en) * 1991-12-12 1993-07-19 Schering Corporation Compounds and compositions for treating HIV infections
CA2084800A1 (en) * 1991-12-16 1993-06-17 Joseph P. Vacca Hiv protease inhibitors with an internal lactam ring
ATE253050T1 (de) 1992-03-11 2003-11-15 Narhex Ltd Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen
WO1993018006A1 (en) * 1992-03-11 1993-09-16 Narhex Limited Amine derivatives of oxo- and hydroxy-substitued hydrocarbons
US6071895A (en) * 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
US5888992A (en) * 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
DE4215874A1 (de) * 1992-05-14 1993-11-18 Bayer Ag Dithiolanylglycinhaltige HIV-Proteaseinhibitoren vom Hydroxyethylenisostertyp
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
IL106507A (en) * 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
US7141609B2 (en) 1992-08-25 2006-11-28 G.D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
EP0810209B1 (en) 1992-08-25 2002-06-05 G.D. Searle & Co. Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
GB2270914A (en) * 1992-09-14 1994-03-30 Merck & Co Inc HIV protease inhibitor compounds
US5430150A (en) * 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5538997A (en) * 1993-03-12 1996-07-23 Sandoz Ltd. 2,4-diamino-3-hydroxycarboxylic acid derivatives
WO1994026749A1 (en) * 1993-05-14 1994-11-24 Merck & Co., Inc. Hiv protease inhibitors
EP0626178A1 (de) * 1993-05-17 1994-11-30 Ciba-Geigy Ag Verwendung von Hemmstoffen von HIV-Aspartatproteasen zur Bekämpfung von Tumorerkrankungen
US5733882A (en) * 1994-01-17 1998-03-31 Smithkline Beecham Corporation Retroviral protease inhibitors
US5476874A (en) * 1994-06-22 1995-12-19 Merck & Co., Inc. New HIV protease inhibitors
ATE220661T1 (de) * 1994-10-19 2002-08-15 Novartis Erfind Verwalt Gmbh Antivirale ether von aspartat-protease-substrat- isosteren
US5691368A (en) * 1995-01-11 1997-11-25 Hoechst Marion Roussel, Inc. Substituted oxazolidine calpain and/or cathepsin B inhibitors
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
AU712071B2 (en) * 1996-04-04 1999-10-28 Shionogi & Co., Ltd. Anti-HIV composition containing imidazole derivatives
US5811462A (en) * 1996-05-02 1998-09-22 Merck & Co., Inc. HIV Protease inhibitors useful for the treatment of AIDS
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
ATE285396T1 (de) 1998-06-19 2005-01-15 Vertex Pharma Sulfonamide als aspartyl-protease-inhibitoren
WO1999067417A2 (en) 1998-06-23 1999-12-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Fitness assay and associated methods
AR031520A1 (es) * 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
US6384244B2 (en) 2000-05-18 2002-05-07 Merck & Co., Inc. Process for preparing cis- aminochromanols
US6531617B2 (en) 2000-10-24 2003-03-11 Merck & Co., Inc. Process for preparing hydroxychomanones and cis-aminochromanols
JP4741121B2 (ja) * 2001-08-29 2011-08-03 株式会社吉谷機械製作所 作業車
DE10207177A1 (de) * 2002-02-19 2003-09-04 Novosom Ag Fakultativ kationische Lipide
DE10207178A1 (de) * 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
US20080076740A1 (en) * 2005-07-27 2008-03-27 Gilead Sciences, Inc. Antiviral compounds
US11175724B2 (en) 2017-03-01 2021-11-16 Samsung Electronics Co., Ltd Method and electronic device for enabling at least one battery management function for managing battery usage

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
FI906212A (fi) 1991-06-19
FI906212A0 (fi) 1990-12-17
IL96691A0 (en) 1991-09-16
CN1053607A (zh) 1991-08-07
HU908295D0 (en) 1991-06-28
PT96234A (pt) 1991-10-15
NO905428D0 (no) 1990-12-17
JPH05345775A (ja) 1993-12-27
CA2032259A1 (en) 1991-06-19
IE904555A1 (en) 1991-06-19
NO905428L (no) 1991-06-19
EP0434365A3 (en) 1991-11-27
AU6822990A (en) 1991-06-27
EP0434365A2 (en) 1991-06-26

Similar Documents

Publication Publication Date Title
KR910011818A (ko) Aids 치료에 유용한 hiv 프로테아제 억제제
KR101799009B1 (ko) 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물
JP2003528072A (ja) マトリックスメタロプロテアーゼおよびＴＮＦ−αの阻害剤としての環状β−アミノ酸誘導体
JP3216136B2 (ja) 抗不整脈ベンゾジアゼピン類
KR930005985A (ko) Hiv 역전사효소의 억제제
US20060004073A1 (en) Compounds, compositions, and methods
EA012607B1 (ru) НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
JPH05279337A (ja) Ａｉｄｓの治療に有用なｈｉｖプロテアーゼ阻害剤
KR20060131908A (ko) Ｃｂ1-길항 활성을 갖는 이미다졸린 유도체
CN101646651A (zh) 具有脲结构的新型吡啶羧酸（2-氨基苯基）酰胺衍生物
AU649812B2 (en) New benzopyran compounds, process for preparing these and pharmaceutical compositions containing them
GB2294264A (en) Dioxobutanioc acid derivatives as inhibitors of influenza endonuclease
KR20010108518A (ko) 카밤산 유도체 및 메타보트로픽 글루타메이트 수용체리간드로서의 그의 용도
DE69635114T2 (de) Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids
US5442055A (en) Azetidinone compound and process for preparation thereof
KR950032185A (ko) 신규한 단일환상 및 이중환상 dna 자이레이즈 저해제
CN101300226A (zh) 对组蛋白脱乙酰酶具有抑制活性的烷基氨甲酰基萘氧基辛烯酰基羟基酰胺衍生物及其制备方法
KR20040039495A (ko) 신규 4-(2-푸로일)아미노피페리딘, 그의 합성 중간체,그의 제조방법 및 의약으로서의 그의 용도
JPH05222020A (ja) エイズの治療に有用なｈｉｖプロテアーゼインヒビター
KR950010894A (ko) 자궁 섬유증의 억제 방법
KR950703557A (ko) 약제로서 사용되는 헤테로아릴 화합물(Heteroaryl Compounds Used as Pharmaceuticals)
CN102372653A (zh) 二苯甲醇类衍生物、其制备方法及其在医药上的应用
EP3768661B1 (en) Deuterated compounds as rock inhibitors
ZA200407709B (en) Novel chalcone derivatives and uses thereof.
CA2132829C (en) Novel derivatives of 2,3-dihydro-benzofuranols

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid